Our findings indicate that the absence of Lonp1 exacerbates bleomycin-induced pulmonary fibrosis, yet it remains uncertain whether LONP1 activators could be utilized as a therapeutic strategy for IPF. This evidence concerns the gene LONP1 and idiopathic pulmonary fibrosis.